Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05206149
Other study ID # GST-intranasale
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date October 1, 2021
Est. completion date December 31, 2021

Study information

Verified date January 2022
Source Azienda Ospedaliera Città della Salute e della Scienza di Torino
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The diagnosis of secondary hypoadrenalism and GH deficiency (GHD) often requires the performance of a dynamic test. The glucagon stimulation test (GST) is one of the options for evaluating hypothalamic-pituitary function, representing a stimulus for both the corticotropic and somatotropic axis, substantially safe and easily available. The standard procedure involves the intramuscular injection of 1-1.5 mg of glucagon based on the patient's weight. In addition to its antero-pituitary function, glucagon has also shown its ability to stimulate neurohypophyseal secretion. Using the copeptin dosage, it has been shown that after the administration of glucagon in healthy subjects there is a significant release of ADH. However, the available data are scarse and there is no standardized protocol for the use of the glucagon test in diabetes insipidus. At the moment, GST is not the most frequently chosen diagnostic option. In fact, despite having the advantage of being able to investigate different areas of anterohypophyseal and probably posterohypophyseal function at the same time, the test has some disadvantages: the prolonged duration makes the procedure challenging, the intramuscular injection can be unwelcome, and many variables can come into play in the definition of a normal response (age, BMI, glycemic status). The recent introduction of a single-dose nasal powder formulation (Baqsimi®) could overcome some of the limitations of classic GST and make the procedure less demanding. To date, no assessments are yet available regarding a purely diagnostic role in the context of hypopituitarism of this new formulation. Through the knowledge of the physiological response of the adrenocortical, somatotropic and ADH axis to the administration of intranasal glucagon in healthy subjects, it will be possible to evaluate its possible application in the diagnosis of GH deficiency, central adrenal insufficiency and possibly diabetes insipidus.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date December 31, 2021
Est. primary completion date December 31, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Any adult healthy subject (age >= 18 years old) and not meeting the exclusion criteria listed below Exclusion Criteria: - BMI < 18.5 kg/m2 or > 25 kg/m2 - Any active pharmacological treatment - Pregnancy or breastfeeding

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Intranasal glugagon
Intranasal glucagon is administered at the dose of 3 mg. This corresponds to the administration of a single dose of Baqsimi®.
Intranasal placebo
Intranasal placebo (represented by isotonic saline solution) is administered.

Locations

Country Name City State
Italy AOU Città della Salute e della Scienza Torino Piemonte

Sponsors (1)

Lead Sponsor Collaborator
Azienda Ospedaliera Città della Salute e della Scienza di Torino

Country where clinical trial is conducted

Italy, 

References & Publications (10)

Arvat E, Maccagno B, Ramunni J, Giordano R, Broglio F, Gianotti L, Maccario M, Camanni F, Ghigo E. Interaction between glucagon and hexarelin, a peptidyl GH secretagogue, on somatotroph and corticotroph secretion in humans. Eur J Endocrinol. 2000 Nov;143(5):601-6. — View Citation

Berg C, Meinel T, Lahner H, Yuece A, Mann K, Petersenn S. Diagnostic utility of the glucagon stimulation test in comparison to the insulin tolerance test in patients following pituitary surgery. Eur J Endocrinol. 2010 Mar;162(3):477-82. doi: 10.1530/EJE-09-0824. Epub 2009 Dec 8. — View Citation

Boguszewski CL. Glucagon stimulation test: has its time come? Endocrine. 2017 Sep;57(3):361-363. doi: 10.1007/s12020-017-1356-8. Epub 2017 Jun 23. — View Citation

Dichtel LE, Yuen KC, Bredella MA, Gerweck AV, Russell BM, Riccio AD, Gurel MH, Sluss PM, Biller BM, Miller KK. Overweight/Obese adults with pituitary disorders require lower peak growth hormone cutoff values on glucagon stimulation testing to avoid overdiagnosis of growth hormone deficiency. J Clin Endocrinol Metab. 2014 Dec;99(12):4712-9. doi: 10.1210/jc.2014-2830. — View Citation

Giuffrida FM, Berger K, Monte L, Oliveira CH, Hoff AO, Maciel RM, Vieira JG. Relationship between GH response and glycemic fluctuations in the glucagon stimulation test. Growth Horm IGF Res. 2009 Feb;19(1):77-81. doi: 10.1016/j.ghir.2008.06.002. Epub 2008 Aug 3. — View Citation

Guzman CB, Dulude H, Piché C, Rufiange M, Sadoune AA, Rampakakis E, Carballo D, Triest M, Zhang MX, Zhang S, Tafreshi M, Sicard E. Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial. Diabetes Obes Metab. 2018 Mar;20(3):646-653. doi: 10.1111/dom.13134. Epub 2017 Nov 19. — View Citation

Hamrahian AH, Yuen KC, Gordon MB, Pulaski-Liebert KJ, Bena J, Biller BM. Revised GH and cortisol cut-points for the glucagon stimulation test in the evaluation of GH and hypothalamic-pituitary-adrenal axes in adults: results from a prospective randomized multicenter study. Pituitary. 2016 Jun;19(3):332-41. doi: 10.1007/s11102-016-0712-7. — View Citation

Lewandowski KC, Lewinski A, Skowronska-Józwiak E, Stasiak M, Horzelski W, Brabant G. Copeptin under glucagon stimulation. Endocrine. 2016 May;52(2):344-51. doi: 10.1007/s12020-015-0783-7. Epub 2015 Nov 17. — View Citation

Sherr JL, Ruedy KJ, Foster NC, Piché CA, Dulude H, Rickels MR, Tamborlane WV, Bethin KE, DiMeglio LA, Fox LA, Wadwa RP, Schatz DA, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators. Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes. Diabetes Care. 2016 Apr;39(4):555-62. doi: 10.2337/dc15-1606. Epub 2016 Feb 16. — View Citation

Yuen KC, Biller BM, Katznelson L, Rhoads SA, Gurel MH, Chu O, Corazzini V, Spiller K, Gordon MB, Salvatori R, Cook DM. Clinical characteristics, timing of peak responses and safety aspects of two dosing regimens of the glucagon stimulation test in evaluating growth hormone and cortisol secretion in adults. Pituitary. 2013 Jun;16(2):220-30. doi: 10.1007/s11102-012-0407-7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in serum ACTH levels between baseline and 15 minutes after glucagon/placebo administration The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum ACTH (ng/L) at baseline (0 minutes) and after 15 minutes from glucagon/placebo administration. From baseline (0 minutes) to 15 minutes after glucagon/placebo administration
Primary Change in serum ACTH levels between baseline and 30 minutes after glucagon/placebo administration The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum ACTH (ng/L) at baseline (0 minutes) and after 30 minutes from glucagon/placebo administration. From baseline (0 minutes) to 30 minutes after glucagon/placebo administration
Primary Change in serum ACTH levels between baseline and 45 minutes after glucagon/placebo administration The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum ACTH (ng/L) at baseline (0 minutes) and after 45 minutes from glucagon/placebo administration. From baseline (0 minutes) to 45 minutes after glucagon/placebo administration
Primary Change in serum ACTH levels between baseline and 60 minutes after glucagon/placebo administration The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum ACTH (ng/L) at baseline (0 minutes) and after 60 minutes from glucagon/placebo administration. From baseline (0 minutes) to 60 minutes after glucagon/placebo administration
Primary Change in serum ACTH levels between baseline and 75 minutes after glucagon/placebo administration The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum ACTH (ng/L) at baseline (0 minutes) and after 75 minutes from glucagon/placebo administration. From baseline (0 minutes) to 75 minutes after glucagon/placebo administration
Primary Change in serum ACTH levels between baseline and 90 minutes after glucagon/placebo administration The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum ACTH (ng/L) at baseline (0 minutes) and after 90 minutes from glucagon/placebo administration. From baseline (0 minutes) to 90 minutes after glucagon/placebo administration
Primary Change in serum ACTH levels between baseline and 120 minutes after glucagon/placebo administration The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum ACTH (ng/L) at baseline (0 minutes) and after 120 minutes from glucagon/placebo administration. From baseline (0 minutes) to 120 minutes after glucagon/placebo administration
Primary Change in serum ACTH levels between baseline and 150 minutes after glucagon/placebo administration The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum ACTH (ng/L) at baseline (0 minutes) and after 150 minutes from glucagon/placebo administration. From baseline (0 minutes) to 150 minutes after glucagon/placebo administration
Primary Change in serum ACTH levels between baseline and 180 minutes after glucagon/placebo administration The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum ACTH (ng/L) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration. From baseline (0 minutes) to 180 minutes after glucagon/placebo administration
Primary Change in serum cortisol levels between baseline and 15 minutes after glucagon/placebo administration The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum cortisol (µg/L) at baseline (0 minutes) and after 15 minutes from glucagon/placebo administration. From baseline (0 minutes) to 15 minutes after glucagon/placebo administration
Primary Change in serum cortisol levels between baseline and 30 minutes after glucagon/placebo administration The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum cortisol (µg/L) at baseline (0 minutes) and after 30 minutes from glucagon/placebo administration. From baseline (0 minutes) to 30 minutes after glucagon/placebo administration
Primary Change in serum cortisol levels between baseline and 45 minutes after glucagon/placebo administration The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum cortisol (µg/L) at baseline (0 minutes) and after 45 minutes from glucagon/placebo administration. From baseline (0 minutes) to 45 minutes after glucagon/placebo administration
Primary Change in serum cortisol levels between baseline and 60 minutes after glucagon/placebo administration The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum cortisol (µg/L) at baseline (0 minutes) and after 60 minutes from glucagon/placebo administration. From baseline (0 minutes) to 60 minutes after glucagon/placebo administration
Primary Change in serum cortisol levels between baseline and 75 minutes after glucagon/placebo administration The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum cortisol (µg/L) at baseline (0 minutes) and after 75 minutes from glucagon/placebo administration. From baseline (0 minutes) to 75 minutes after glucagon/placebo administration
Primary Change in serum cortisol levels between baseline and 90 minutes after glucagon/placebo administration The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum cortisol (µg/L) at baseline (0 minutes) and after 90 minutes from glucagon/placebo administration. From baseline (0 minutes) to 90 minutes after glucagon/placebo administration
Primary Change in serum cortisol levels between baseline and 120 minutes after glucagon/placebo administration The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum cortisol (µg/L) at baseline (0 minutes) and after 120 minutes from glucagon/placebo administration. From baseline (0 minutes) to 120 minutes after glucagon/placebo administration
Primary Change in serum cortisol levels between baseline and 150 minutes after glucagon/placebo administration The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum cortisol (µg/L) at baseline (0 minutes) and after 150 minutes from glucagon/placebo administration. From baseline (0 minutes) to 150 minutes after glucagon/placebo administration
Primary Change in serum cortisol levels between baseline and 180 minutes after glucagon/placebo administration The response of the corticotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum cortisol (µg/L) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration. From baseline (0 minutes) to 180 minutes after glucagon/placebo administration
Primary Change in serum GH levels between baseline and 15 minutes after glucagon/placebo administration The response of the somatotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum GH (µg/L) at baseline (0 minutes) and after 15 minutes from glucagon/placebo administration. From baseline (0 minutes) to 15 minutes after glucagon/placebo administration
Primary Change in serum GH levels between baseline and 30 minutes after glucagon/placebo administration The response of the somatotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum GH (µg/L) at baseline (0 minutes) and after 30 minutes from glucagon/placebo administration. From baseline (0 minutes) to 30 minutes after glucagon/placebo administration
Primary Change in serum GH levels between baseline and 45 minutes after glucagon/placebo administration The response of the somatotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum GH (µg/L) at baseline (0 minutes) and after 45 minutes from glucagon/placebo administration. From baseline (0 minutes) to 45 minutes after glucagon/placebo administration
Primary Change in serum GH levels between baseline and 60 minutes after glucagon/placebo administration The response of the somatotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum GH (µg/L) at baseline (0 minutes) and after 60 minutes from glucagon/placebo administration. From baseline (0 minutes) to 60 minutes after glucagon/placebo administration
Primary Change in serum GH levels between baseline and 75 minutes after glucagon/placebo administration The response of the somatotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum GH (µg/L) at baseline (0 minutes) and after 75 minutes from glucagon/placebo administration. From baseline (0 minutes) to 75 minutes after glucagon/placebo administration
Primary Change in serum GH levels between baseline and 90 minutes after glucagon/placebo administration The response of the somatotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum GH (µg/L) at baseline (0 minutes) and after 90 minutes from glucagon/placebo administration. From baseline (0 minutes) to 90 minutes after glucagon/placebo administration
Primary Change in serum GH levels between baseline and 120 minutes after glucagon/placebo administration The response of the somatotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum GH (µg/L) at baseline (0 minutes) and after 120 minutes from glucagon/placebo administration. From baseline (0 minutes) to 120 minutes after glucagon/placebo administration
Primary Change in serum GH levels between baseline and 150 minutes after glucagon/placebo administration The response of the somatotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum GH (µg/L) at baseline (0 minutes) and after 150 minutes from glucagon/placebo administration. From baseline (0 minutes) to 150 minutes after glucagon/placebo administration
Primary Change in serum GH levels between baseline and 180 minutes after glucagon/placebo administration The response of the somatotroph axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring serum GH (µg/L) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration. From baseline (0 minutes) to 180 minutes after glucagon/placebo administration
Primary Change in plasma copeptin levels between baseline and 15 minutes after glucagon/placebo administration The response of the antidiuretic axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring plasma copeptin (pmol/L) at baseline (0 minutes) and after 15 minutes from glucagon/placebo administration. From baseline (0 minutes) to 15 minutes after glucagon/placebo administration
Primary Change in plasma copeptin levels between baseline and 30 minutes after glucagon/placebo administration The response of the antidiuretic axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring plasma copeptin (pmol/L) at baseline (0 minutes) and after 30 minutes from glucagon/placebo administration. From baseline (0 minutes) to 30 minutes after glucagon/placebo administration
Primary Change in plasma copeptin levels between baseline and 45 minutes after glucagon/placebo administration The response of the antidiuretic axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring plasma copeptin (pmol/L) at baseline (0 minutes) and after 45 minutes from glucagon/placebo administration. From baseline (0 minutes) to 45 minutes after glucagon/placebo administration
Primary Change in plasma copeptin levels between baseline and 60 minutes after glucagon/placebo administration The response of the antidiuretic axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring plasma copeptin (pmol/L) at baseline (0 minutes) and after 60 minutes from glucagon/placebo administration. From baseline (0 minutes) to 60 minutes after glucagon/placebo administration
Primary Change in plasma copeptin levels between baseline and 75 minutes after glucagon/placebo administration The response of the antidiuretic axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring plasma copeptin (pmol/L) at baseline (0 minutes) and after 75 minutes from glucagon/placebo administration. From baseline (0 minutes) to 75 minutes after glucagon/placebo administration
Primary Change in plasma copeptin levels between baseline and 90 minutes after glucagon/placebo administration The response of the antidiuretic axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring plasma copeptin (pmol/L) at baseline (0 minutes) and after 90 minutes from glucagon/placebo administration. From baseline (0 minutes) to 90 minutes after glucagon/placebo administration
Primary Change in plasma copeptin levels between baseline and 120 minutes after glucagon/placebo administration The response of the antidiuretic axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring plasma copeptin (pmol/L) at baseline (0 minutes) and after 120 minutes from glucagon/placebo administration. From baseline (0 minutes) to 120 minutes after glucagon/placebo administration
Primary Change in plasma copeptin levels between baseline and 150 minutes after glucagon/placebo administration The response of the antidiuretic axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring plasma copeptin (pmol/L) at baseline (0 minutes) and after 150 minutes from glucagon/placebo administration. From baseline (0 minutes) to 150 minutes after glucagon/placebo administration
Primary Change in plasma copeptin levels between baseline and 180 minutes after glucagon/placebo administration The response of the antidiuretic axis to the administration of intranasal glucagon, compared to placebo, was evaluated by measuring plasma copeptin (pmol/L) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration. From baseline (0 minutes) to 180 minutes after glucagon/placebo administration
Secondary Change in serum sodium levels between baseline and 15 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum sodium (mmol/L) at baseline (0 minutes) and after 15 minutes from glucagon/placebo administration. From baseline (0 minutes) to 15 minutes after glucagon/placebo administration
Secondary Change in serum sodium levels between baseline and 30 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum sodium (mmol/L) at baseline (0 minutes) and after 30 minutes from glucagon/placebo administration. From baseline (0 minutes) to 30 minutes after glucagon/placebo administration
Secondary Change in serum sodium levels between baseline and 45 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum sodium (mmol/L) at baseline (0 minutes) and after 45 minutes from glucagon/placebo administration. From baseline (0 minutes) to 45 minutes after glucagon/placebo administration
Secondary Change in serum sodium levels between baseline and 60 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum sodium (mmol/L) at baseline (0 minutes) and after 60 minutes from glucagon/placebo administration. From baseline (0 minutes) to 60 minutes after glucagon/placebo administration
Secondary Change in serum sodium levels between baseline and 75 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum sodium (mmol/L) at baseline (0 minutes) and after 75 minutes from glucagon/placebo administration. From baseline (0 minutes) to 75 minutes after glucagon/placebo administration
Secondary Change in serum sodium levels between baseline and 90 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum sodium (mmol/L) at baseline (0 minutes) and after 90 minutes from glucagon/placebo administration. From baseline (0 minutes) to 90 minutes after glucagon/placebo administration
Secondary Change in serum sodium levels between baseline and 120 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum sodium (mmol/L) at baseline (0 minutes) and after 120 minutes from glucagon/placebo administration. From baseline (0 minutes) to 120 minutes after glucagon/placebo administration
Secondary Change in serum sodium levels between baseline and 150 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum sodium (mmol/L) at baseline (0 minutes) and after 150 minutes from glucagon/placebo administration. From baseline (0 minutes) to 150 minutes after glucagon/placebo administration
Secondary Change in serum sodium levels between baseline and 180 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum sodium (mmol/L) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration. From baseline (0 minutes) to 180 minutes after glucagon/placebo administration
Secondary Change in serum potassium levels between baseline and 15 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum potassium (mmol/L) at baseline (0 minutes) and after 15 minutes from glucagon/placebo administration. From baseline (0 minutes) to 15 minutes after glucagon/placebo administration
Secondary Change in serum potassium levels between baseline and 30 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum potassium (mmol/L) at baseline (0 minutes) and after 30 minutes from glucagon/placebo administration. From baseline (0 minutes) to 30 minutes after glucagon/placebo administration
Secondary Change in serum potassium levels between baseline and 45 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum potassium (mmol/L) at baseline (0 minutes) and after 45 minutes from glucagon/placebo administration. From baseline (0 minutes) to 45 minutes after glucagon/placebo administration
Secondary Change in serum potassium levels between baseline and 60 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum potassium (mmol/L) at baseline (0 minutes) and after 60 minutes from glucagon/placebo administration. From baseline (0 minutes) to 60 minutes after glucagon/placebo administration
Secondary Change in serum potassium levels between baseline and 75 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum potassium (mmol/L) at baseline (0 minutes) and after 75 minutes from glucagon/placebo administration. From baseline (0 minutes) to 75 minutes after glucagon/placebo administration
Secondary Change in serum potassium levels between baseline and 90 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum potassium (mmol/L) at baseline (0 minutes) and after 90 minutes from glucagon/placebo administration. From baseline (0 minutes) to 90 minutes after glucagon/placebo administration
Secondary Change in serum potassium levels between baseline and 120 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum potassium (mmol/L) at baseline (0 minutes) and after 120 minutes from glucagon/placebo administration. From baseline (0 minutes) to 120 minutes after glucagon/placebo administration
Secondary Change in serum potassium levels between baseline and 150 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum potassium (mmol/L) at baseline (0 minutes) and after 150 minutes from glucagon/placebo administration. From baseline (0 minutes) to 150 minutes after glucagon/placebo administration
Secondary Change in serum potassium levels between baseline and 180 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum potassium (mmol/L) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration. From baseline (0 minutes) to 180 minutes after glucagon/placebo administration
Secondary Change in plasma osmolality between baseline and 15 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma osmolality (mOsm/kg) at baseline (0 minutes) and after 15 minutes from glucagon/placebo administration. From baseline (0 minutes) to 15 minutes after glucagon/placebo administration
Secondary Change in plasma osmolality between baseline and 30 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma osmolality (mOsm/kg) at baseline (0 minutes) and after 30 minutes from glucagon/placebo administration. From baseline (0 minutes) to 30 minutes after glucagon/placebo administration
Secondary Change in plasma osmolality between baseline and 45 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma osmolality (mOsm/kg) at baseline (0 minutes) and after 45 minutes from glucagon/placebo administration. From baseline (0 minutes) to 45 minutes after glucagon/placebo administration
Secondary Change in plasma osmolality between baseline and 60 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma osmolality (mOsm/kg) at baseline (0 minutes) and after 60 minutes from glucagon/placebo administration. From baseline (0 minutes) to 60 minutes after glucagon/placebo administration
Secondary Change in plasma osmolality between baseline and 75 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma osmolality (mOsm/kg) at baseline (0 minutes) and after 75 minutes from glucagon/placebo administration. From baseline (0 minutes) to 75 minutes after glucagon/placebo administration
Secondary Change in plasma osmolality between baseline and 90 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma osmolality (mOsm/kg) at baseline (0 minutes) and after 90 minutes from glucagon/placebo administration. From baseline (0 minutes) to 90 minutes after glucagon/placebo administration
Secondary Change in plasma osmolality between baseline and 120 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma osmolality (mOsm/kg) at baseline (0 minutes) and after 120 minutes from glucagon/placebo administration. From baseline (0 minutes) to 120 minutes after glucagon/placebo administration
Secondary Change in plasma osmolality between baseline and 150 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma osmolality (mOsm/kg) at baseline (0 minutes) and after 150 minutes from glucagon/placebo administration. From baseline (0 minutes) to 150 minutes after glucagon/placebo administration
Secondary Change in plasma osmolality between baseline and 180 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma osmolality (mOsm/kg) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration. From baseline (0 minutes) to 180 minutes after glucagon/placebo administration
Secondary Change in serum glucose levels between baseline and 15 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum glucose (mg/dl) at baseline (0 minutes) and after 15 minutes from glucagon/placebo administration. From baseline (0 minutes) to 15 minutes after glucagon/placebo administration
Secondary Change in serum glucose levels between baseline and 30 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum glucose (mg/dl) at baseline (0 minutes) and after 30 minutes from glucagon/placebo administration. From baseline (0 minutes) to 30 minutes after glucagon/placebo administration
Secondary Change in serum glucose levels between baseline and 45 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum glucose (mg/dl) at baseline (0 minutes) and after 45 minutes from glucagon/placebo administration. From baseline (0 minutes) to 45 minutes after glucagon/placebo administration
Secondary Change in serum glucose levels between baseline and 60 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum glucose (mg/dl) at baseline (0 minutes) and after 60 minutes from glucagon/placebo administration. From baseline (0 minutes) to 60 minutes after glucagon/placebo administration
Secondary Change in serum glucose levels between baseline and 75 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum glucose (mg/dl) at baseline (0 minutes) and after 75 minutes from glucagon/placebo administration. From baseline (0 minutes) to 75 minutes after glucagon/placebo administration
Secondary Change in serum glucose levels between baseline and 90 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum glucose (mg/dl) at baseline (0 minutes) and after 90 minutes from glucagon/placebo administration. From baseline (0 minutes) to 90 minutes after glucagon/placebo administration
Secondary Change in serum glucose levels between baseline and 120 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum glucose (mg/dl) at baseline (0 minutes) and after 120 minutes from glucagon/placebo administration. From baseline (0 minutes) to 120 minutes after glucagon/placebo administration
Secondary Change in serum glucose levels between baseline and 150 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum glucose (mg/dl) at baseline (0 minutes) and after 150 minutes from glucagon/placebo administration. From baseline (0 minutes) to 150 minutes after glucagon/placebo administration
Secondary Change in serum glucose levels between baseline and 180 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring serum glucose (mg/dl) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration. From baseline (0 minutes) to 180 minutes after glucagon/placebo administration
Secondary Change in plasma insulin levels between baseline and 15 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma insulin (mU/L) at baseline (0 minutes) and after 15 minutes from glucagon/placebo administration. From baseline (0 minutes) to 15 minutes after glucagon/placebo administration
Secondary Change in plasma insulin levels between baseline and 30 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma insulin (mU/L) at baseline (0 minutes) and after 30 minutes from glucagon/placebo administration. From baseline (0 minutes) to 30 minutes after glucagon/placebo administration
Secondary Change in plasma insulin levels between baseline and 45 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma insulin (mU/L) at baseline (0 minutes) and after 45 minutes from glucagon/placebo administration. From baseline (0 minutes) to 45 minutes after glucagon/placebo administration
Secondary Change in plasma insulin levels between baseline and 60 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma insulin (mU/L) at baseline (0 minutes) and after 60 minutes from glucagon/placebo administration. From baseline (0 minutes) to 60 minutes after glucagon/placebo administration
Secondary Change in plasma insulin levels between baseline and 75 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma insulin (mU/L) at baseline (0 minutes) and after 75 minutes from glucagon/placebo administration. From baseline (0 minutes) to 75 minutes after glucagon/placebo administration
Secondary Change in plasma insulin levels between baseline and 90 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma insulin (mU/L) at baseline (0 minutes) and after 90 minutes from glucagon/placebo administration. From baseline (0 minutes) to 90 minutes after glucagon/placebo administration
Secondary Change in plasma insulin levels between baseline and 120 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma insulin (mU/L) at baseline (0 minutes) and after 120 minutes from glucagon/placebo administration. From baseline (0 minutes) to 120 minutes after glucagon/placebo administration
Secondary Change in plasma insulin levels between baseline and 150 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma insulin (mU/L) at baseline (0 minutes) and after 150 minutes from glucagon/placebo administration. From baseline (0 minutes) to 150 minutes after glucagon/placebo administration
Secondary Change in plasma insulin levels between baseline and 180 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring plasma insulin (mU/L) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration. From baseline (0 minutes) to 180 minutes after glucagon/placebo administration
Secondary Change in urine sodium levels between baseline and 180 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring urine sodium (mmol/L) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration. From baseline (0 minutes) to 180 minutes after glucagon/placebo administration
Secondary Change in urine potassium levels between baseline and 180 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring urine potassium (mmol/L) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration. From baseline (0 minutes) to 180 minutes after glucagon/placebo administration
Secondary Change in urine creatinine levels between baseline and 180 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring urine creatinine (mg/dl) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration. From baseline (0 minutes) to 180 minutes after glucagon/placebo administration
Secondary Change in urine osmolality between baseline and 180 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of glycometabolic and hydro-electrolyte biochemical balance was evaluated by measuring urine osmolality (mOsm/kg) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration. From baseline (0 minutes) to 180 minutes after glucagon/placebo administration
Secondary Change in resistance at bioimpedance vector analysis between baseline and 180 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of bioimpedance vector analysis (BIVA) was evaluated by measuring resistance (Ohm) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration. From baseline (0 minutes) to 180 minutes after glucagon/placebo administration
Secondary Change in reactance at bioimpedance vector analysis between baseline and 180 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of bioimpedance vector analysis (BIVA) was evaluated by measuring reactance (Ohm) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration. From baseline (0 minutes) to 180 minutes after glucagon/placebo administration
Secondary Change in phase angle at bioimpedance vector analysis between baseline and 180 minutes after glucagon/placebo administration The response to the administration of intranasal glucagon, compared to placebo, in terms of bioimpedance vector analysis (BIVA) was evaluated by measuring phase angle (°) at baseline (0 minutes) and after 180 minutes from glucagon/placebo administration. From baseline (0 minutes) to 180 minutes after glucagon/placebo administration
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02871986 - Pubertal Induction in Individuals With Hypogonadism N/A
Completed NCT00851942 - Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test Phase 4
Completed NCT00507104 - Pituitary Functions After Traumatic Brain Injury (TBI) and/or Subarachnoid Hemorrhage (SAH)
Completed NCT01088399 - A Prospective Observational Study of Effect of Somatropin on Growth Hormone Deficient Adults N/A
Completed NCT00027430 - Androgen Replacement Therapy in Women With Hypopituitarism N/A
Recruiting NCT04897802 - Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study) Phase 4
Not yet recruiting NCT06014398 - Improving Survivorship and Health-related Quality of Life in Patients With Primary Brain Tumours N/A
Recruiting NCT04121780 - Growth Hormone Replacement Therapy for Retried Professional Football Players Phase 2
Not yet recruiting NCT01666964 - Hormone Deficiency After Brain Injury During Combat N/A
Completed NCT01028742 - Posttraumatic Hypopituitarism - Incidence, Predictors and Test Validity N/A
Completed NCT00139945 - Ghrelin, Growth Hormone and Cortisol Interaction in Growth Hormone Deficient Patients N/A
Completed NCT05188131 - Acute Neuroendocrine Response to Intravenous Infusion of Diclofenac Sodium Phase 4
Completed NCT00133354 - Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys Phase 2/Phase 3
Not yet recruiting NCT03708523 - Next Day Growth Hormone Predicting Pituitary Function After Adenomectomy
Completed NCT01007071 - Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency Phase 3
Not yet recruiting NCT06326853 - Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models
Completed NCT00080483 - Testosterone and Growth Hormone for Bone Loss in Men Phase 2
Completed NCT01009905 - An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone) N/A
Completed NCT01209416 - The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin N/A
Recruiting NCT04902235 - Identification and Clinical Relevance of an Oxytocin Deficient State (CRH Study) Phase 4